| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | TOBIRA THERAPEUTICS INC | 2,668,570 | 33,517,000 | 26.73% | ||
| 2 | GLAUKOS CORP | 867,788 | 25,305,000 | 20.18% | ||
| 3 | COLLEGIUM PHARMACEUTICAL INC COM | 1,887,332 | 22,365,000 | 17.84% | ||
| 4 | AMICUS THERAPEUTICS INC | 2,725,591 | 14,882,000 | 11.87% | ||
| 5 | CIDARA THERAPEUTICS INC | 1,312,258 | 13,529,000 | 10.79% | ||
| 6 | Lion Biotechnologies | 774,720 | 6,275,000 | 5.00% | ||
| 7 | IGNYTA INC COM | 950,366 | 5,151,000 | 4.11% | ||
| 8 | ProNAi Therapeutics, Inc. | 2,186,195 | 4,351,000 | 3.47% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001420506-16-001157, filed 2016.08.09).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
